Ovid Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Ovid Therapeutics Inc. (Nasdaq: OVID) is a New York-based, clinical-stage biopharmaceutical company dedicated to pioneering better, gentler small molecule medicines for brain disorders driven by neuronal hyperexcitability. The company's strategic focus centers on two primary therapeutic platforms: OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor designed to treat drug-resistant seizures with improved safety and reduced ocular toxicity compared to older agents; and a robust library of potassium-chloride cotransporter 2 (KCC2) direct activators, led by the oral candidate OV4071, targeting multiple central nervous system (CNS) disorders including schizophrenia, neurodevelopmental conditions, and psychoses.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing a first-in-class franchise of potassium-chloride cotransporter 2 (KCC2) direct activators designed to restore inhibitory tone in the brain. This includes clinical development of OV4071 (oral formulation) and preclinical/IND-enabling studies of next-generation compounds.
Expected impact: Establishes a sustainable pipeline of oral and injectable molecules targeting psychosis, behavior/mood disorders, and seizures.
Developing OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor, for drug-resistant focal onset seizures (FOS) and developmental and epileptic encephalopathies (DEEs). The program is expanding into pediatric indications including tuberous sclerosis complex (TSC) seizures and infantile spasms (IS).
Expected impact: Provides a highly differentiated, safer, and more tolerable anti-seizure therapeutic option compared to older generation GABA-AT inhibitors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Ovid sold its future royalty rights for ganaxolone outside of China to Immedica, providing a non-dilutive capital infusion to support Ovid's core pipeline while offloading ganaxolone IP maintenance costs.
Terms: $7 million upfront cash payment to Ovid. Immedica also acquires or licenses Ovid's global ganaxolone IP portfolio and assumes financial responsibility for all associated IP costs.